BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

read more >>

4th International Course on Antibiotics and Resistance (ICARe)

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

read more >>

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

read more >>

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100

Dr. Glenn Dale, Chief Development Officer of BioVersys: “We are very pleased to receive QIDP designation from the FDA for…

read more >>

Latest news of BEAM Alliance

page 1/2

next

Latest news of BEAM Members

previous

page 3/14

next

Events

page 1/3

next